FETAL DISTRESS AND NEONATAL ASPHYXIA: DIAGNOSTIC METHODS, TREATMENT PRINCIPLES, COMPLICATIONS, AND NEONATAL RESUSCITATION PRINCIPLES

Fetal distress and neonatal asphyxia represent critical perinatal emergencies characterized by impaired oxygen delivery to the fetus or newborn, leading to hypoxic-ischemic injury, multi-organ dysfunction, and potentially fatal outcomes if not promptly addressed. This extensively expanded review synthesizes the latest evidence on diagnostic approaches, including Apgar scoring, umbilical cord blood gas analysis, fetal heart rate monitoring, electroencephalography (EEG), and neuroimaging; treatment principles encompassing immediate resuscitation, therapeutic hypothermia (TH), pharmacological interventions, and supportive care; complications such as hypoxic-ischemic encephalopathy (HIE), seizures, cardiovascular instability, renal failure, and long-term neurodevelopmental impairments; and neonatal resuscitation principles guided by the Neonatal Resuscitation Program (NRP) algorithms from the American Academy of Pediatrics (AAP) and American Heart Association (AHA). Drawing from epidemiological data, clinical trials, meta-analyses, and cohort studies spanning 2010-2025, we report global incidence rates of neonatal asphyxia at 1-8 per 1,000 live births in high-resource settings and up to 20-50 per 1,000 in low- and middle-income countries (LMICs), with severe cases leading to mortality in 10-20% and morbidity in 25-50% of survivors. Pathophysiologically, fetal distress often manifests as abnormal fetal heart rate patterns (e.g., late decelerations, bradycardia) due to uteroplacental insufficiency, cord compression, or maternal factors like hypertension, while neonatal asphyxia progresses from primary apnea to gasping, bradycardia, and secondary apnea, necessitating rapid intervention to prevent irreversible brain damage via excitotoxicity, oxidative stress, and apoptosis. The topic's urgency is amplified by its contribution to over 800,000 annual neonatal deaths worldwide, disproportionately affecting LMICs due to limited access to monitoring and intensive care, highlighting the need for scalable, cost-effective strategies. High innovative potential lies in integrating artificial intelligence (AI) for real-time fetal monitoring, biomarker assays (e.g., S100B, neuron-specific enolase), advanced neuroimaging like magnetic resonance spectroscopy (MRS), and telemedicine for remote resuscitation guidance. Treatment efficacy is evidenced by TH reducing death or disability by 25-30% in moderate-severe HIE, while NRP-compliant resuscitation improves survival by 30-40%. Complications extend to systemic effects, with HIE grading (mild, moderate, severe per Sarnat staging) predicting outcomes: mild cases often resolve without sequelae, moderate carry 20-30% risk of cerebral palsy, and severe up to 80% mortality or profound disability. This article expands on prior syntheses by incorporating socioeconomic analyses, ethical considerations in resource allocation, cross-cultural variations in management, pandemic impacts (e.g., COVID-19-related delays), climate influences on maternal health, and emerging therapies like erythropoietin, stem cells, and xenon inhalation. By providing a multidisciplinary framework blending obstetrics, neonatology, neurology, and public health, we aim to equip clinicians, researchers, and policymakers with actionable insights to optimize early detection, personalized interventions, and long-term follow-up, ultimately reducing the global burden of perinatal asphyxia and fostering equitable neonatal health outcomes.

Ҳали таржима қилинмаган